Erschienen in:
23.02.2017 | Multiple Myeloma (P Kapoor, Section Editor)
CARs in the Lead Against Multiple Myeloma
verfasst von:
Maria Ormhøj, Felipe Bedoya, Matthew J. Frigault, Marcela V. Maus
Erschienen in:
Current Hematologic Malignancy Reports
|
Ausgabe 2/2017
Einloggen, um Zugang zu erhalten
Abstract
The recent clinical success of CD19-directed chimeric antigen receptor (CAR) T cell therapy in chronic and acute leukemia has led to increased interest in broadening this technology to other hematological malignancies and solid tumors. Now, advances are being made using CAR T cell technology to target myeloma antigens such as B cell maturation antigen (BCMA), CD138, and kappa-light chain as well as CD19 on putative myeloma stem cells. To date, only a limited number of multiple myeloma patients have received CAR T cell therapy but preliminary results have been encouraging. In this review, we summarize the recently reported results of clinical trials conducted utilizing CAR T cell therapy in multiple myeloma (MM).